Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 173

recruiting
3 982
countries
28
conditions
2 106

2 730 trials match your criteria

Renal cell carcinoma

Not recruiting

Study of Belzutifan with Lenvatinib versus Cabozantinib in Adults with Advanced Renal Cell Carcinoma Who Have Previously Received Anti-PD-1/L1 Treatment

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Belzutifan

HIV infection

Not recruiting

Study on Budigalimab and ABBV-382 for People with HIV on Stable Antiretroviral Therapy

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Budigalimab

Non-small cell lung cancer stage IV

Not recruiting

Study of Pembrolizumab, Favezelimab, and Lenvatinib for Patients with Advanced Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Favezelimab

Squamous cell carcinoma of lung

Not recruiting

Study of Pembrolizumab, Carboplatin, and Paclitaxel for Patients with Metastatic Squamous Non-small Cell Lung Cancer

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Neoplasm malignant+1

Not recruiting

Study on the Safety and Tolerability of Spartalizumab for Patients with Advanced Cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Canakinumab

Squamous cell carcinoma of lung+3

Not recruiting

Study Comparing Subcutaneous and Intravenous Pembrolizumab with Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Spinal muscular atrophy

Not recruiting

Study on Long-Term Safety and Effects of Apitegromab in Patients with Type 2 and TYPE 3 Spinal Muscular Atrophy Who Completed Previous Trials

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years
  • Substances:Apitegromab

Hormone receptor positive breast cancer

Not recruiting

Study of OP-1250 for Treating Advanced or Metastatic ER+, HER2- Breast Cancer in Patients After Endocrine and CDK4/6 Inhibitor Therapy

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole

Essential thrombocythaemia

Not recruiting

Study on Bomedemstat for Patients with Essential Thrombocythemia Not Responding to or Intolerant of Hydroxyurea, Comparing with a Drug Combination

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Bomedemstat

Colitis ulcerative+1

Not recruiting

Study on the Long-term Safety of Vedolizumab for Children with Ulcerative Colitis or Crohn's Disease

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Vedolizumab

Immunoglobulin G4 related disease

Not recruiting

Study on the Effectiveness of Inebilizumab for Patients with IgG4-Related Disease

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Inebilizumab

Small cell lung cancer extensive stage

Not recruiting

Study on the Effectiveness and Safety of Pembrolizumab, Quavonlimab, and Lenvatinib for Patients with Advanced Small Cell Lung Cancer Needing Second-Line Treatment

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Favezelimab

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.